Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gavoille Antoine, Leray Emmanuelle, Marignier Romain, Rollot Fabien, Casey Romain, Mathey Guillaume, Michel Laure, De Seze Jerome, Ciron Jonathan, Ruet Aurélie, Maillart Elisabeth, Labauge Pierre, Zephir Helene, Laplaud David Axel, Papeix Caroline, Defer Gilles, Moreau Thibault, Berger Eric, Dubessy Anne-Laure, Clavelou Pierre, Thouvenot Eric, Heinzlef Olivier, Pelletier Jean, Al Khedr Abdullatif, Casez Olivier, Bourre Bertrand, Wahab Abir, Magy Laurent, Camdessanche Jean-Philippe, Doghri Ines, Moulin Solène, Labeyrie Celine, Hankiewicz Karolina, Dos Santos Amélie, Pottier Corinne, Manchon Eric, Tchikviladze Maya, Lebrun-Frenay Christine, Vukusic Sandra, OFSEP investigators
Аннотация
METHODS: We performed a retrospective cohort study based on data extracted on June 2023 from the Observatoire Français de la Sclérose en Plaques for all patients with a relapsing-remitting MS onset between 18 and 40 years. The primary outcome was the annual probability of receiving a DMT, accounting for sex, disease severity, and pregnancy/postpartum periods. Secondary outcomes were the annual probability of receiving a HEDMT, each DMT separately, and interaction of the effect of sex with calendar year, patient age, and disease duration. We used a longitudinal logistic model with generalized estimating equations and an inverse-probability-of-censoring weighting.
RESULTS: We included 22,657 patients with MS; 16,857 (74.4%) were female, mean (SD) age at onset was 29.0 (6.0) years, and median (interquartile range) follow-up duration was 11.6 (6.6-17.3) years. Women were significantly less likely to receive a DMT (odds ratio [OR] 0.92, 95% CI 0.87-0.97) or a HEDMT (OR 0.80, 95% CI 0.74-0.86). This difference appeared 2 years after disease onset for DMTs and 1 year for HEDMTs, and did not differ significantly according to patient's age. Teriflunomide, sphingosine-1-phosphate receptor modulators, and anti-CD20s were significantly underused in women throughout their entire period of availability; interferons β (IFN-β) and natalizumab were initially less used and then equally after some time; glatiramer acetate and fumarates were first used equally, then more frequently in women. The proportion of treated women, analyzed from the first childbirth of 5,268 women, began to decline 18 months before childbirth, from 42.6% to 27.9% at the estimated time of conception.
DISCUSSION: Women with MS were significantly less exposed to DMTs compared with men. Anticipation of pregnancy was probably an important factor underlying this difference, but also sex-specific therapeutic inertia. Neurologists and patients should be educated on the most recent recommendations on the use of DMTs in the context of pregnancy to avoid deleterious therapeutic inertia.